BPC-157 10mg

BPC-157 10mg — Body Protection Compound

Isolated from human gastric juice, studied in over 100 preclinical papers, and detected in biological samples up to 4 days post-administration (He et al., Frontiers in Pharmacology, 2022) — BPC-157 is a 15-amino-acid pentadecapeptide that has been examined across an unusually broad range of experimental systems. Tendons. Ligaments. Muscle. Bone. Gastric mucosa. Intestinal anastomoses. Blood vessels. Neurons. Most research peptides are studied in one or two tissue types. BPC-157 10mg has been studied in nearly all of them.

Specifications

Sequence	Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
One-Letter Code	GEPPPGKPADDAGLV
Molecular Formula	C62H98N16O22
Molecular Weight	1419.53 g/mol
CAS Number	137525-51-0
PubChem CID	108101
Form	Lyophilized powder
Quantity	10mg per vial

Connective tissue research

Chang et al. documented tendon outgrowth, cell survival, and migration linked to F-actin formation and FAK-paxillin pathway activation in tendon fibroblast cultures (J Applied Physiology, 2011; PubMed 21030672).

Gastrointestinal research

This is where BPC-157 10mg was first characterized. Sikiric et al. coined the “stable gastric pentadecapeptide” label after documenting cytoprotective properties across gastric lesion, IBD, and intestinal anastomosis models (Curr Pharm Design, 2018; PubMed 29998800).

Nitric oxide pathways

Research has examined BPC-157 10mg in the context of VEGFR2-Akt-eNOS signaling and experimental angiogenesis. Huang et al. documented ERK1/2 phosphorylation and downstream transcription factor activation in vascular models (Drug Design, Development and Therapy, 2015; DOI 10.2147/DDDT.S82030).

Neuroprotective research

Vukojevic et al. reviewed BPC-157 interactions within CNS experimental models including traumatic brain injury systems (Neural Regeneration Research, 2022; PubMed 34380872).

BPC-157 vs TB-500

Both appear in tissue recovery protocols, but the mechanisms are distinct. BPC-157 10mg: GI integrity, connective tissue, NO pathway modulation. TB-500: actin regulation, cell migration, cardiac tissue, blood vessel formation. Complementary, not redundant. Available individually or as a BPC-TB blend.

BPC-157 10mg is Frequently paired with

• TB-500 10mg — Available as BPC-TB Blend.
• GHK-Cu 50mg — Available in Glow 50/10/10.
• LL-37 10mg — Immune pathway research.

Quality and testing

Every batch is independently tested with mass spectrometry identity confirmation. Lyophilized in the United States. Pure peptide — no mannitol, no bulking agents, no excipients. Batch-specific COAs available.

Storage

• Lyophilized: -20°C
• Reconstituted: 2-8°C, use within 30 days
• Protection: Shield from light and moisture; avoid freeze-thaw cycles

References

1. Chang CH, et al. J Applied Physiology. 2011;110(3):774-780. PubMed 21030672
2. Seiwerth S, et al. Curr Pharm Design. 2018;24(18):1972-1989. PubMed 29998800
3. Sikiric P, et al. Curr Pharm Design. 2014;20(7):1126-1135. PubMed 23755727
4. Vukojevic J, et al. Neural Regen Res. 2022;17(3):482-487. PubMed 34380872
5. Huang T, et al. Drug Design Dev Ther. 2015. DOI 10.2147/DDDT.S82030
6. He L, et al. Front Pharmacol. 2022;13:1026182.

FAQ

What is BPC-157?

A 15-amino-acid synthetic peptide originally identified from human gastric juice. Over 100 preclinical studies across connective tissue, GI, vascular, and neurological models.

BPC-157 vs TB-500?

Different mechanisms. BPC-157: gastrointestinal integrity, connective tissue, nitric oxide pathways. TB-500: actin dynamics, cell migration, cardiac tissue. Complementary, not interchangeable.

Is BPC-157 approved for human use?

No. It is a research compound not evaluated or approved by the FDA. Peptide Bio Sciences LTD products are strictly for laboratory research.

For laboratory research use only. Not for human or veterinary use. Not a drug, food, or cosmetic.